Alira Health

Alira Health
Contact us
Alira Health
Menu
Home > Education Hub > Advances in Biologics and CGT

Advances in Biologics and CGT

September 28, 5 - 7:30pm EDT | Cambridge, MA

We are excited to share that we will be joining the Advances in Biologics and CGT Networking Reception hosted by Catalent. This event will bring C-suite executives, and venture capital investors for an invite only Happy Hour at Cambridge’s Biotech hub.

Sean Forestell, Director, CMC Operations of Alira Health will be joining a discussion “Unveiling Biologic and Cell & Gene Therapy Market Trends” among other industry experts, uncovering the latest trends and advancements in the Biologics and Cell & Gene Therapy markets.

If you would like to take a deeper dive into the rapidly growing global Biologics and Advanced Therapies market, download our latest 2023 Biologics and Advanced Therapies Contract Manufacturing Report.

 

Our Speaker
Events
Category:
Biologics CMC
Published on:
September 27, 2023
Sean Forestell

Sean Forestell

 Director, CMC Operations Sean Forestell, Ph.D. is an expert in biologics process development and manufacturing with over 30 years of experience in the biotech industry, including senior leadership roles at BioMarin, Genentech, and Novartis. Dr. Forestell’s broad experience includes viral vectors used in cell and gene therapy, monoclonal antibodies, and enzymes to treat ultra rare diseases that are produced using continuous manufacturing technologies. He has been involved in the successful technology transfer of 12 early-stage clinical products and four successful process performance qualifications (PPQs), and has supported the manufacture of eight different commercial products. Dr. Forestell earned a B.Sc. in biological engineering at the University of Guelph and a Ph.D. in chemical engineering from the University of Calgary. He has co-authored 19 articles in peer-reviewed journals and is an inventor on two issued patents.

Related news

News July 22, 2026
Specialized Manufacturing Capability Emerges as the New Competitive Advantage in the $23.2 Billion Global Biologics CDMO Market, Finds Alira Health
Alira Health, a global healthcare consultancy, today released the 2026 Biologics Contract Manufacturing Report, its annual analysis of the global contract development and manufacturing(...)
Biologics CDMO Contract Manufacturing
Reports and White Papers July 21, 2026
The 2026 Biologics Contract Manufacturing Report
Discover the latest biologics CDMO market insights on manufacturing, investment, and M&A trends shaping the industry. Access the 2026 report today.
Advanced Therapies Biologics CDMO
Articles May 15, 2026
Four Capabilities Redefining Competitive Advantage in Biologics CDMOs in 2026
Learn how biologics CDMO leaders strengthen competitive advantage in 2026 with resilient networks, AI-driven execution, and disciplined capital strategies.
Biologics CDMO
Events March 23, 2026
TIDES USA 2026
Meet Alira Health’s CMC experts onsite to discuss your product development challenges and CDMO selection needs.
CMC USA
Reports and White Papers March 20, 2026
2026 Biologics CDMO Public Market Update
Access public biologics CDMO valuation trends, global competitive dynamics, IPO and equity market signals, investment flows, and capacity expansion outlook.
Biologics CDMO
Reports and White Papers October 22, 2025
The 2025 Global Biosimilars Report
This report provides an assessment of trends in the global biosimilar market, with an emphasis on market and competitive dynamics in the US and Europe.
Biologics Biosimilars
Articles September 10, 2025
Biologics CDMOs Market in 2025: Key Growth Drivers and Challenges
Discover how the biologics CDMO industry grows in 2025, driven by AT demand and digital innovation, while navigating cost, supply, and geopolitical challenges.
Biologics CDMO
See all news
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.